Tislelizumab uniquely binds to the CC′ loop of PD‐1 with slow‐dissociated rate and complete PD‐L1 blockage-Reference-Cited by-同舟云学术

Tislelizumab uniquely binds to the CC′ loop of PD‐1 with slow‐dissociated rate and complete PD‐L1 blockage

Published:2021-02-16 Issue:3 Volume:11 Page:782-792
ISSN:2211-5463
Container-title:FEBS Open Bio
language:en
Short-container-title:FEBS Open Bio

Author:

Hong Yuan¹^ORCID,Feng Yingcai¹,Sun Hanzi¹,Zhang Bo¹,Wu Hongfu¹,Zhu Qing¹,Li Yucheng¹,Zhang Tong¹,Zhang Yilu¹,Cui Xinxin¹,Li Zhuo¹,Song Xiaomin¹,Li Kang¹,Liu Mike¹,Liu Ye¹^ORCID

Affiliation:

1. BeiGene Global Research BeiGene (Beijing) Co., Ltd. China

Publisher

Wiley

Subject

General Biochemistry, Genetics and Molecular Biology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/2211-5463.13102

Reference32 articles.

1. THE B7 FAMILY REVISITED

2. Inhibitory B7-family molecules in the tumour microenvironment

3. Molecular mechanisms of T cell co-stimulation and co-inhibition

4. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

5. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An in silico investigation on the binding site preference of PD-1 and PD-L1 for designing antibodies for targeted cancer therapy;PLOS ONE;2024-07-25

2. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial;Journal of Thoracic Oncology;2024-07

3. Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/ mismatch repair-deficient solid tumors;CHINESE J CANCER RES;2024

4. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial;BMJ;2024-05-28

5. Structural insights into the unique pH-responsive characteristics of the anti-TIGIT therapeutic antibody Ociperlimab;Structure;2024-05